good morning all... imcl news, jane...
Wednesday September 22, 7:30 am Eastern Time
Company Press Release
ImClone Systems Files Registration Statement for Public Offering
NEW YORK--(BW HealthWire)--Sept. 22, 1999--ImClone Systems Incorporated (Nasdaq: IMCL - news) today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a public offering of 2.5 million primary shares of Common Stock. Following the offering, the Company will have approximately 28 million shares of Common Stock outstanding, assuming no exercise of the underwriters\022 375,000 share over-allotment option. The offering is being underwritten by Morgan Stanley Dean Witter, Merrill Lynch & Co., Prudential Vector Healthcare Group, a unit of Prudential Securities and Warburg Dillon Read LLC.
ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale could be unlawful prior to registration or qualification under the securities laws of any such state.
--------------------------------------------------------------------------------
Contact:
ImClone Systems Incorporated
Andrea F. Rabney
Senior Director of Corporate Development
Investor Relations
(212) 645-1405
www.imclone.com
or
Burns McClellan, Inc.
Jonathan Nugent (investors)
Justin Jackson (media)
(212) 213-0006
--------------------------------------------------------------------------------
More Quotes and News: Imclone Systems Inc (Nasdaq:IMCL - news)
Related News Categories: biotech, medical/pharmaceutical
|
